RE:RE:...and this, we do not know..Hi Toinv,
Just read your post after posting mine, I understand and share a lot of your frustration. I definitely got the impression from the AGM and from discussion after the presentations that management at RVX feel that through these trials and subsequent analysis they have been learning a great deal about RVX-208 and been given the opportunity to further refine their target market as well as vastly refine the next trial and through this process now have a realistic opportunity to see this through to a successful business conclusion. The market for CVD diabetics is huge, I've read north of 10 million people in the US alone, and I can't believe that a big pharma wouldn't consider this to be an incredible pipeline asset should the phase II/III trial be successful. Especially since big pharma pipelines in general are not currently all that strong.
As far as Zenith goes I kind of hope they are in no rush tpo IPO because it seems to me that private companies have been getting higher valuations than public ones in the recent past.